All Oncology News

After a re-examination procedure, the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion on the conditional marketing authorization application for adagrasib in the treatment of adult patients with KRAS G12C–mutated advanced non–small cell lung cancer whose disease progressed following at least 1 prior systemic treatment.

Bayer has announced the intention to voluntarily withdraw the new drug application for copanlisib in adult patients with relapsed follicular lymphoma who have previously received at least 2 prior systemic treatments.

Stephen V. Liu, MD, discusses strategies for treatment and disease management for patients with advanced non–small cell lung cancer who are awaiting biomarker test results.

Treatment with the novel immunotherapy PV-10 led to hepatic responses in patients with metastatic uveal melanoma with liver metastases, according to updated data from a phase 1 trial.

Ongoing research evaluating combination therapies for the frontline treatment of patients with EGFR-mutated non–small cell lung cancer could help improve survival outcomes for this patient population.

Nicholas C. Rohs, MD, delves into the details of the case study a patient who had a lung cancer relapse detected following a referral to a dermatologist due to pityriasis rubra pilaris.

In a new paper in JCO Oncology Practice, bioethics researchers at Dana-Farber Cancer Institute call on medical societies, government leaders, clinicians, and researchers to work together to ensure AI-driven healthcare preserves patient autonomy and respects human dignity.

TerSera Therapeutics LLC announced that The National Comprehensive Cancer Network Head and Neck Cancers Panel recommended the GnRH agonist goserelin for patients with recurrent, unresectable, or metastatic salivary gland tumors who were not eligible for surgery or radiation therapy.

Benjamin Besse, MD, PhD, discusses the results from the ATALANTE-1 trial and details the mechanism of action of the OSE2101 vaccine.

Andrew L. Ji, MD, is working to better understand cutaneous squamous cell carcinoma —a skin cancer that is the second most common cancer in the United States and one that causes substantial morbidity, with a considerable risk for metastatic spread and death.

While there are considerable barriers to incorporating comprehensive genotyping, the use of circulating tumor DNA offers an improvement in molecular testing—and doing so earlier can accelerate the time to treatment and improve survival for patients with lung cancer.

As treatments for patients with stage IV non–small cell lung cancer continue to evolve, patients with PD-L1–negative disease represent a unique cohort and chemotherapy/immunotherapy or immunotherapy doublet regimens appear to be effective.

Although not immediately practice changing, CAR T-cell therapy has the potential to become a standard of care for patients with advanced renal cell carcinoma following progression on checkpoint inhibitors and VEGF inhibitors.

Additional research exploring the association between clonal hematopoiesis and cardiovascular health could help improve outcomes for patients with kidney cancer and identify those at higher risk for experiencing cardiac events.

Further understanding of the cancer immunity cycle could drive the development of novel immune therapies for patients with renal cell carcinoma.

Decisions regarding the intensification or de-escalation of treatment, particularly with immunotherapy and TKIs, for patients with renal cell carcinoma could be aided by circulating tumor DNA.

Although the emergence of immunotherapy have created additional treatment options for patients with various types of cancer, these agents are associated with significant toxicities and immune-related adverse effects.

The National Cancer Institute has awarded the Icahn School of Medicine at Mount Sinai a $3.4 million grant to create a model that identifies the best prostate cancer treatment for people with HIV.

Administration of the hypoxia-inducible factor–2α inhibitor belzutifan (Welireg) at the recommended phase 2 dose of 120 mg daily produced comparable toxicities and efficacy outcomes to that of a daily 200-mg dose of the agent in patients with advanced clear cell renal cell carcinoma.

Treatment with zanzalintinib monotherapy produced antitumor activity and was well tolerated in patients with previously treated advanced clear cell renal cell carcinoma.

Jaleh Fallah, MD, discusses the FDA's evaluation of data from the phase 2 LITESPARK-004 trial, which supported the approval of belzutifan in von Hippel-Lindau–associated cancers.

Improvements in screening, systemic therapy, and precision medicine have reduced breast cancer mortality and morbidity, and further progress will hinge on the use of ctDNA and CTCs for disease monitoring, continued development of novel antiestrogenic agents, and movement of ADCs and immunotherapy into expanded settings and indications.

Howard I. Scher, MD, sheds light on various research programs he has led or has been heavily involved with that have helped change the course of prostate cancer treatment over the years.

The combination of enfortumab vedotin-ejfv plus pembrolizumab represents a chemotherapy-free regimen that could alter the standard of care in the frontline treatment of all patients with metastatic urothelial carcinoma.

Immune checkpoint inhibitors have been associated with improved outcomes for patients with metastatic translocation renal cell carcinoma; however, novel therapies and therapeutic targets are needed for patients within this histologic subset.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of pembrolizumab (Keytruda) combined with gemcitabine and cisplatin in the frontline treatment of adult patients with locally advanced unresectable or metastatic biliary tract cancer

Henkel Valentine, PhD, a postdoctoral fellow in the lab of Philip Abbosh, MD, PhD, in the Nuclear Dynamics and Cancer Research Program at Fox Chase Cancer Center, was one of six postdoctoral researchers nationwide recently recognized as an IMPACT Fellow by the National Postdoctoral Association.

Research has continued to focus on developing novel therapies and bringing new treatments to the sarcoma treatment paradigm.

Alexander Kutikov, MD, FACS, chair of the Department of Urology and the Roberta R. Scheller Chair in Urologic Oncology at Fox Chase Cancer Center, will receive the Andrew C. Novick Award from the Kidney Cancer Association.

The mitigation and management of toxicities is a key component of treating patients with biliary tract cancers with targeted therapies.